Currently, drugs inhibiting the pro-inflammatory interleukin-6 (IL-6), such as Ziltivekimab and Clazakizumab, are undergoing clinical trials for atherosclerosis therapy (see review [29]). The gene discussed is IL6; the disease is atherosclerosis.